Hanall Biopharma Asset Resilience Ratio
Hanall Biopharma asset resilience ratio. Hanall Biopharma (009420) has an Asset Resilience Ratio of 3.91% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 009420 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hanall Biopharma (2011–2024)
Asset resilience ratio of Hanall Biopharma from 2011 to 2024. This chart shows how Hanall Biopharma's Asset Resilience Ratio has changed over time. Read Hanall Biopharma balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hanall Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hanall Biopharma assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩8.32 Billion | 3.91% |
| Total Liquid Assets | ₩8.32 Billion | 3.91% |
Asset Resilience Insights
- Limited Liquidity: Hanall Biopharma maintains only 3.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hanall Biopharma Industry Peers by Asset Resilience Ratio
Compare Hanall Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Hanall Biopharma Asset Resilience Ratio by Year (2011–2024)
Hanall Biopharma asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Hanall Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.91% | ₩8.32 Billion ≈ $5.64 Million |
₩212.88 Billion ≈ $144.27 Million |
-5.59pp |
| 2023-12-31 | 9.50% | ₩22.77 Billion ≈ $15.43 Million |
₩239.75 Billion ≈ $162.47 Million |
-7.88pp |
| 2022-12-31 | 17.38% | ₩37.09 Billion ≈ $25.14 Million |
₩213.45 Billion ≈ $144.65 Million |
-16.77pp |
| 2021-12-31 | 34.15% | ₩67.78 Billion ≈ $45.93 Million |
₩198.48 Billion ≈ $134.51 Million |
-5.15pp |
| 2020-12-31 | 39.30% | ₩86.51 Billion ≈ $58.62 Million |
₩220.13 Billion ≈ $149.18 Million |
-7.37pp |
| 2019-12-31 | 46.67% | ₩89.31 Billion ≈ $60.53 Million |
₩191.38 Billion ≈ $129.70 Million |
+5.59pp |
| 2018-12-31 | 41.08% | ₩66.67 Billion ≈ $45.18 Million |
₩162.30 Billion ≈ $109.99 Million |
+9.26pp |
| 2017-12-31 | 31.82% | ₩53.67 Billion ≈ $36.37 Million |
₩168.70 Billion ≈ $114.32 Million |
-4.62pp |
| 2016-12-31 | 36.43% | ₩45.44 Billion ≈ $30.80 Million |
₩124.73 Billion ≈ $84.53 Million |
+3.16pp |
| 2015-12-31 | 33.28% | ₩38.98 Billion ≈ $26.41 Million |
₩117.13 Billion ≈ $79.37 Million |
+26.11pp |
| 2014-12-31 | 7.17% | ₩6.25 Billion ≈ $4.23 Million |
₩87.17 Billion ≈ $59.07 Million |
+0.16pp |
| 2013-12-31 | 7.01% | ₩6.86 Billion ≈ $4.65 Million |
₩97.85 Billion ≈ $66.31 Million |
-12.27pp |
| 2012-12-31 | 19.27% | ₩23.95 Billion ≈ $16.23 Million |
₩124.27 Billion ≈ $84.22 Million |
+11.34pp |
| 2011-12-31 | 7.93% | ₩8.36 Billion ≈ $5.67 Million |
₩105.46 Billion ≈ $71.47 Million |
-- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more